Published in N Engl J Med on January 27, 2005
Rituximab Vasculitis Maintenance Study (RITAZAREM) | NCT01697267
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis | NCT00468208
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Macrophage diversity in renal injury and repair. J Clin Invest (2008) 4.41
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Pulmonary vasculitis. Proc Am Thorac Soc (2006) 2.54
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum (2013) 2.17
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther (2009) 1.98
ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol (2010) 1.67
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) (2010) 1.45
ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity. Clin Rheumatol (2014) 1.38
The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med (2005) 1.28
Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep (2010) 1.17
Pediatric vasculitis. Pediatr Clin North Am (2012) 1.17
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis (2008) 1.12
Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol (2006) 1.11
Bench-to-bedside review: pulmonary-renal syndromes--an update for the intensivist. Crit Care (2007) 1.10
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol (2007) 1.08
The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol (2011) 1.06
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol (2011) 1.04
High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med (2010) 1.04
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (2014) 0.99
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther (2009) 0.99
Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) (2012) 0.99
Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol (2009) 0.98
Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab. Ann Rheum Dis (2006) 0.97
Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 0.97
Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J (2015) 0.97
Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor (2009) 0.95
An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol (2010) 0.95
Diffuse alveolar hemorrhage. Tuberc Respir Dis (Seoul) (2013) 0.94
Management of ANCA-associated vasculitis: Current trends and future prospects. Ther Clin Risk Manag (2010) 0.93
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther (2011) 0.93
Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.93
Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum (2008) 0.93
The impact of vasculitis on patients' social participation and friendships. Clin Exp Rheumatol (2012) 0.92
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) (2011) 0.91
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol (2011) 0.89
Is serum HMGB1 a biomarker in ANCA-associated vasculitis? Arthritis Res Ther (2013) 0.88
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis (2010) 0.87
Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol (2015) 0.87
Malignancy risk in vasculitis. Ther Adv Musculoskelet Dis (2011) 0.87
Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum (2011) 0.86
Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol (2012) 0.86
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum (2008) 0.85
Current status of outcome measure development in vasculitis. J Rheumatol (2014) 0.85
Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol (2009) 0.84
Treatment of renal manifestations of ANCA-associated vasculitis. J Nephropathol (2013) 0.84
Anti-TNF-alpha therapy and systemic vasculitis. Mediators Inflamm (2014) 0.84
Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis (2006) 0.83
Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. J Clin Oncol (2014) 0.83
Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. Arch Pathol Lab Med (2014) 0.83
Vasculitis treatment - new therapeutic approaches. Eur J Pediatr (2006) 0.82
Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Semin Arthritis Rheum (2013) 0.82
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis (2013) 0.82
ANCA-associated vasculitides-lessons from the adult literature. Pediatr Nephrol (2010) 0.82
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis). Ther Clin Risk Manag (2014) 0.82
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther (2015) 0.81
Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity. Clin Immunol (2009) 0.81
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol (2015) 0.81
Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol Online J (2016) 0.80
Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol (2012) 0.80
T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol (2014) 0.80
ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol (2016) 0.80
Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int (2008) 0.79
[Histopathology of systemic vasculitis]. Pathologe (2010) 0.79
Recalcitrant granulomatous sclerouveitis in a patient with granulomatous ANCA-associated vasculitis. Ocul Immunol Inflamm (2009) 0.78
What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J (2015) 0.78
Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol (2010) 0.78
Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol (2012) 0.78
Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS One (2014) 0.78
Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. Semin Arthritis Rheum (2014) 0.78
Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis (2014) 0.78
Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge. Clin Exp Otorhinolaryngol (2016) 0.78
[Vasculitis: histopathology and differential diagnosis]. Z Rheumatol (2009) 0.77
TNF-α inhibitors: are they carcinogenic? Drug Healthc Patient Saf (2010) 0.77
Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. Clin Exp Immunol (2006) 0.77
Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Ann Rheum Dis (2007) 0.77
A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors. Ann Rheum Dis (2006) 0.77
[Foudroyant course of a therapy resistent Wegener's granulomatosis with negative c-ANCA]. Mund Kiefer Gesichtschir (2007) 0.77
Vaccination under TNF blockade - less effective, but worthwhile. Arthritis Res Ther (2012) 0.77
Cytokines: Names and Numbers You Should Care About. Clin J Am Soc Nephrol (2015) 0.77
Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association? Clin Rheumatol (2011) 0.77
Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report. Pediatr Rheumatol Online J (2011) 0.77
The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag (2007) 0.76
C-reactive protein enhances activation of coagulation system and inflammatory response through dissociating into monomeric form in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunol (2015) 0.76
ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol (2009) 0.76
Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail. J Am Soc Nephrol (2014) 0.76
Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol (2006) 0.76
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clin Exp Rheumatol (2009) 0.76
[Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement]. Z Rheumatol (2008) 0.76
New-generation therapy for ANCA-associated vasculitis. Clin Exp Nephrol (2013) 0.76
Cyclosporin-A associated malignancy. Clin Ophthalmol (2007) 0.76
Targeting the B cell in vasculitis. Pediatr Nephrol (2008) 0.75
Bilateral idiopathic orbital inflammation 3 years before systemic Wegener's granulomatosis in a 7-year-old girl. Clin Ophthalmol (2008) 0.75